The Quantellect read.As of Nov 19, 2026, 10 active firms cover Perspective Therapeutics Inc: 9 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-1.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy990%
Neutral110%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 19, 2026 vs $0.78 current
Highest Target—
Average Target—
Lowest Target—
CATX analyst recommendation trends
129630
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
7
7
8
9
9
9
Neutral
0
0
1
1
1
1
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
7
7
9
10
10
10
As of Nov 19, 2026, 9 of 10 active firms rate CATX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CATX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.28 – $-0.16 · 4 analysts · -1% YoY
Next period, 4 analysts expect Perspective Therapeutics Inc. to earn $-0.25 a share (range $-0.28 – $-0.16), versus $-0.25 a year earlier. Full-year consensus is $-0.97, growing to $-1.03 the year after.
REVENUE · NEXT QUARTER
$87.8K
Range $0 – $251.0K · 4 analysts · +15% YoY
Revenue is expected to reach $87.8K (range $0 – $251.0K), +15.5% year-over-year. Full-year consensus is $147.0K, rising to $281.6K next year.
Top analysts covering Perspective Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CATX.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$11.00+1310.1% to target
Overall win rate
48%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #27
Neutral
$4.00+412.8% to target
Overall win rate
52%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$13.00+1566.5% to target
Overall win rate
42%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #277
Buy
$15.00+1822.8% to target
Overall win rate
35%
+ Follow
#5
Jeff Jones
Oppenheimer · Rank #320
Buy
$13.00+1566.5% to target
Overall win rate
32%
+ Follow
CATX stock forecast FAQ
Is CATX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CATX?+
10 active firms have a recognized rating on Perspective Therapeutics Inc. as of Nov 19, 2026.
Who is the most accurate analyst covering CATX?+
Among analysts who currently cover CATX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $11.00 target.
What is Perspective Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.28 – $-0.16) across 4 analysts. Full-year EPS is projected at $-0.97, rising to $-1.03 the following year.
How much revenue is Perspective Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $87.8K (range $0 – $251.0K). Full-year revenue is projected at $147.0K, growing to $281.6K next year.
Have analysts been upgrading or downgrading CATX lately?+
As of Nov 19, 2026, 9 of 10 active firms rate CATX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CATX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.